Published in AAPS J on October 21, 2010
Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn (2012) 1.01
Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn (2010) 0.93
The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J (2012) 0.86
A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics. AAPS J (2013) 0.83
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol (2015) 0.83
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. J Clin Pharmacol (2011) 0.82
Lifespan based indirect response models. J Pharmacokinet Pharmacodyn (2012) 0.81
Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. AAPS J (2011) 0.79
Bioanalytical method validation: concepts, expectations and challenges in small molecule and macromolecule--a report of PITTCON 2013 symposium. AAPS J (2014) 0.79
Expression, purification and biological activity assessment of romiplostim biosimilar peptibody. Daru (2016) 0.78
Romiplostim dose-response in patients with myelodysplastic syndromes. Br J Clin Pharmacol (2013) 0.77
Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J Pharmacokinet Pharmacodyn (2012) 0.77
Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. AAPS J (2015) 0.75
Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates. Am J Physiol Heart Circ Physiol (2014) 0.75
Normal and pathological dynamics of platelets in humans. J Math Biol (2017) 0.75
A modification of receptor theory. Br J Pharmacol Chemother (1956) 14.20
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood (2001) 2.21
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn (2003) 2.06
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res (2005) 1.96
Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos (2003) 1.93
Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood (1997) 1.87
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood (2002) 1.65
Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther (1994) 1.64
Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol (2003) 1.61
Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther (2004) 1.41
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood (1995) 1.35
Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res (1999) 1.35
Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood (2000) 1.26
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood (2002) 1.25
Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol (2006) 1.22
Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm (1999) 1.17
Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol (1999) 1.13
Human platelets display high-affinity receptors for thrombopoietin. Blood (1997) 1.07
Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev (2002) 1.04
Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J (2007) 1.03
Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet (2008) 1.02
Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects. J Clin Pharmacol (2009) 0.99
Human platelets as a model for the binding and degradation of thrombopoietin. Blood (1997) 0.95
Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci (2004) 0.89
Binding and regulation of thrombopoietin to human megakaryocytes. Br J Haematol (1998) 0.83
Drug concentration, binding, and effect in vivo. Pharm Res (1984) 0.79
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood (2004) 2.37
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res (2005) 1.96
Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet (2011) 1.54
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn (2009) 1.33
Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol (2004) 1.27
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J (2010) 1.10
Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn (2007) 1.08
Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol (2003) 1.07
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther (2006) 1.06
Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J (2007) 1.03
Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med (2004) 1.03
Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet (2008) 1.02
Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J Pharmacokinet Pharmacodyn (2012) 1.01
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol (2007) 0.98
Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn (2004) 0.96
Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol (2007) 0.93
Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet (2012) 0.92
Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet (2009) 0.92
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst (2004) 0.91
Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn (2005) 0.91
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn (2009) 0.91
Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J Pharmacol Exp Ther (2010) 0.90
Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats. Cytometry A (2009) 0.90
Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol (2007) 0.90
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol (2004) 0.90
Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn (2006) 0.89
Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci (2004) 0.89
Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Exp Hematol (2008) 0.88
Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci (2009) 0.88
Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance. J Med Chem (2006) 0.86
The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J (2012) 0.86
Development of biosimilars--pharmacokinetic and pharmacodynamic considerations. J Biopharm Stat (2010) 0.85
Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model. Cytometry A (2007) 0.85
Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients. J Pharm Sci (2013) 0.84
A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats. J Pharm Sci (2002) 0.84
Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. Clin Pharmacokinet (2013) 0.84
Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res (2012) 0.83
Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn (2006) 0.83
Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J (2014) 0.82
Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet (2009) 0.82
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. J Clin Pharmacol (2011) 0.82
Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop. AAPS J (2013) 0.81
D-optimal designs for parameter estimation for indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn (2009) 0.80
The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats. Biopharm Drug Dispos (2014) 0.80
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer (2012) 0.79
Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid. AAPS J (2011) 0.79
Quantification of water diffusion and relaxation times of human U87 tumors in a mouse model. NMR Biomed (2004) 0.79
Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals. Pharm Res (2012) 0.78
Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. J Pharm Sci (2003) 0.78
Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. J Clin Pharmacol (2002) 0.77
Solving delay differential equations in S-ADAPT by method of steps. Comput Methods Programs Biomed (2013) 0.77
Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies. AAPS J (2014) 0.77
Romiplostim dose-response in patients with myelodysplastic syndromes. Br J Clin Pharmacol (2013) 0.77
Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J Pharmacokinet Pharmacodyn (2012) 0.77
Influence of haloperidol and clozapine on some behavioral effects in rats. Arzneimittelforschung (2006) 0.77
Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors. J Clin Pharmacol (2015) 0.77
Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats. Biopharm Drug Dispos (2010) 0.76
Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. J Pharmacokinet Pharmacodyn (2014) 0.76
The effect of epoetin dose on hematocrit. Kidney Int (2008) 0.75
Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS J (2004) 0.75
Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies. Med Oncol (2010) 0.75
Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness. Pharm Res (2012) 0.75
Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development. Anticancer Res (2007) 0.75
Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients. Biopharm Drug Dispos (2010) 0.75
Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)). Clin Pharmacokinet (2012) 0.75